1 |
张晓录,沈安俐,郭睿,等. CD200在急性髓细胞白血病中的表达特点及其临床意义[J]. 中国实验血液学杂志,2014,22(6):1531-1534.
|
2 |
Damiani D, Tiribelli M, Raspadori D, et al. Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors[J]. Oncotarget, 2015, 6(30): 30212-30221.
|
3 |
Lauzon-Joset JF, Langlois A, Lai LJ, et al. Lung CD200 receptor activation abrogates airway hyperresponsiveness in experimental asthma[J]. Am J Respir Cell Mol Biol, 2015, 53 (2): 276-284.
|
4 |
Kawasaki BT, Farrar WL. Cancer stem cells, CD200 and immunoevasion[J]. Trends Immunol, 2008, 29 (10): 464-468.
|
5 |
Alapat D, Coviello-Malle J, Owens R, et al. Diagn-ostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma[J]. Am J Clin Pathol, 2012, 137 (1): 93-100.
|
6 |
Tonks A, Hills R, White P, et al. CD200 as a pro-gnostic factor in acute myeloid leukaemia[J]. Leukemia, 2007, 21 (3): 566-568.
|
7 |
Moreaux J, Hose D, Reme T, et al. CD200 is a new prognostic factor in multiple myeloma[J]. Blood, 2006, 108 (13): 4194-4197.
|
8 |
陈永斌,张敏珍,杨国辉. 细胞免疫功能测定在危重症患者中的临床意义[J/CD]. 中华危重症医学杂志(电子版),2010,3(6):384-388.
|
9 |
Coles SJ, Wang EC, Man S, et al. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia[J]. Leukemia, 2011, 25 (5): 792-799.
|
10 |
Memarian A, Nourizadeh M, Masoumi F, et al. Upr-egulation of CD200 is associated with Foxp3+ regulatory T cell expansion and disease progression in acute myeloid leukemia[J]. Tumour Biol, 2013, 34 (1): 531-542.
|
11 |
Imola M, Mianulli AM, Pasini G, et al. Emergency hemicolectomy for intestinal primary aspergillosis in acute myeloid leukemia[J]. G Chir, 2012, 33 (3): 74-76.
|
12 |
Fonseka M, Ramasamy R, Tan BC, et al. Human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSC) inhibit the proliferation of K562 (human erythromyeloblastoid leukaemic cell line)[J]. Cell Biol Int, 2012, 36 (9): 793-801.
|
13 |
Chen CC, Yang CF, Yang MH, et al. Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia[J]. Ann Oncol, 2005, 16 (8): 1366-1373.
|
14 |
范艳莹,吴长有. IL-4、IL-10和抗IL-12受体β1mAb抑制IL-23诱导正常人记忆T细胞IFN-γ产生[J]. 免疫学杂志,2006,22(4):353-357.
|
15 |
Guo H, Qiao Z, Zhu L, et al. Th1/Th2 cytokine profiles and their relationship to clinical features in patients following nonmyeloablative allogeneic stem cell transplantation[J]. Am J Hematol, 2004, 7 5(2): 78-83.
|
16 |
Harrington LE, Hatton RD, Mangan PR, et al. Int-erleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages[J]. Nat Immunol, 2005, 6 (11): 1123-1132.
|
17 |
Sakaguchi S, Sakaguchi N, Asano M, et al. Imm-unologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases[J]. J Immunol, 1995, 155 (3): 1151-1164.
|
18 |
Gorczynski RM, Lee L, Boudakov I. Augmented in-duction of CD4+CD25+ Treg using monoclonal antibodies to CD200R[J]. Transplantation, 2005, 79 (4): 488-491.
|
19 |
Shenghui Z, Yixiang H, Jianbo W, et al. Elevated frequencies of CD4+CD25+CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia[J]. Int J Cancer, 2011, 129 (6): 1373-1381.
|
20 |
龚晓成,曾辉,韩伟. 胃癌患者外周血CD4+CD25+Foxp3+调节性T细胞55例分析[J/CD]. 中华危重症医学杂志(电子版),2013,6(5):307-309.
|
21 |
Beyer M, Schultze JL. Regulatory T cells: major players in the tumor microenvironment.[J]. Curr Pharm Des, 2009, 15 (16): 1879-1892.
|